American Society for Bone and Mineral Research to Hold 27th Annual Meeting Sept. 23-27 in Nashville, Tenn.
WHAT: The American Society for Bone and Mineral Research (ASBMR) 27th Annual Meeting
WHEN: Sept. 23 to 27
WHERE: ASBMR Media Room, Gaylord Opryland Resort and Convention Center, Nashville, Tenn.
The ASBMR 27th Annual Meeting offers a comprehensive scientific program, presenting groundbreaking research and new clinical treatments in bone diseases and disorders of mineral metabolism, including osteoporosis treatment and prevention.
This yearís Annual Meeting, held in Nashville, Tenn., Sept. 23 to 27, brings together some 5,300 researchers and clinicians from 60 countries.
Highlights include two Plenary Lectures, two Plenary Symposia (on clinical, basic, and translational topics), 12 State-of-the-Art Lectures, four Mini-Symposia, nearly 200 oral presentations, approximately 1,800 poster presentations, and 27 Meet-the-Professor Sessions.
Topics covered at the meeting will include:
-- Bone and mineral complications of chronic kidney disease
-- New trends in the molecular imaging of bone
-- Secondary causes of osteoporosis including gastrointestinal diseases and osteoporosis after treatment of breast cancer
-- The role of the vasculature in bone quality
-- Modeling skeletal disease in genetically engineered mice
-- Diseases of phosphate homeostasis
-- Epidemiology, pathophysiology, diagnosis and treatment of stress fractures
A panel of experts will discuss the latest scientific advances in bone and mineral research on Friday, Sept. 23, at 12 p.m. CDT in Governorís Chamber E at the Gaylord Opryland Hotel and Convention Center.
WHAT: Media briefing announcing the latest science on the diagnosis, prevention and treatment of osteoporosis and other bone and mineral diseases, as well as basic bone biology, that will be presented at the ASBMR 27th Annual Meeting.
WHEN: Friday, Sept. 23 12 p.m., Governorís Chamber E (Annual Meeting dates Sept. 23 to 27)
-- Christian Linden, M.D., Childhood Exercise Significantly Increased Peak Bone Mass
Two studies of the compound AAE581:
-- Sandip Roy, Ph.D., Potential Osteoporosis Treatment Well Tolerated, Effective in First Human Study
-- Christopher Jerome, Ph.D., Novel Compound Protected Against Bone Loss in Monkey Model of Osteoporosis
-- Pierre Delmas, M.D., Study Confirms Strontium Ranelateís Unique, Dual Mode of Action in Treating Osteoporosis.
Dr. Delmas will also present New Device May Predict Fracture Risk
-- Robert Lindsay, M.D., Ph.D., Early Osteoporosis Treatment Reduced Fracture Risk Almost 50 percent
Media Registration and Advance Media Kits
For registration information and to receive an embargoed media kit before the meeting, please contact Melissa Haynes at firstname.lastname@example.org or at 202-367-1219.
- Contact Information
- Melissa Haynes
- Media Contact
- The American Society for Bone and Mineral Research
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.